Page 56 - Merck Sharp News Today

14.11.2022 - Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused ... Seite 1

Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV)...

Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single...

Microbiome clinical trial pipeline constitutes 130+ key companies continuously working towards developing 200+ microbiome drugs, analyzes DelveInsight LAS VEGAS, Nov. 9, 2022 /PRNewswire/

/PRNewswire/ -- DelveInsights Microbiome Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed, and pipeline...

COVID-19 clinical trial pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 vaccines and drugs, analyzes DelveInsight LAS VEGAS, Nov. 8, 2022 /PRNewswire/

PFS2 is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.

VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studiesHMBD-002 in comb...

Scoop Community provides New Zealand Community news and views

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has ...